TOI.V -3.03FFH.TO 5.53TFII.TO 3.91XLV -0.1STLD 9.25DAL 2.29AUTO.L 0.002BARC-O 0
Daily Stock Opinions and Ratings
Stockchase Opinions

Jim Cramer - Mad MoneyNovoCure LimitedNVCRDON'T BUYJan 29, 2025

He used to like this company a lot, but they fail to make money. Revenues are flat.

Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$25.52

Stock price when the opinion was issued

$14.62

As of Oct 27, 2026. Market Open.

Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

BUY

NovoCure Limited(NVCR)

May 03, 2021
The medical community doesn't recognize this company, but when it does the stock will double.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$202.56

Stock price when the opinion was issued

$14.62

As of Oct 27, 2026. Market Open.

Healthcare
BUY

NovoCure Limited(NVCR)

Oct 06, 2020
Recommended this in early-2018. Why has it doubled recently? It works. A friend of his used NVCR medical machines, and his life was extended by three years.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$119.35

Stock price when the opinion was issued

$14.62

As of Oct 27, 2026. Market Open.

Healthcare

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

CGX.TO -0.01$12.92
CVE.TO -2.06$44.48
BN.TO 0.16$53.43
MCD -1.36$249.47
NA.TO 2.65$209.95

Today's Top Picks

TOI.V -3.03$94.52
FFH.TO 5.53$2469.78
TFII.TO 3.91$160.84
XLV -0.1$179.18
STLD 9.25$246.8

Popular Articles

Latest Sell Signals

XEI.TO -0.1$40.44
BCE.TO -0.2$28.23
OWL -0.03$9.31
QNNT 0$
ZCOM.CN 0$

Most Recent Experts

Barry Schwartz

Barry Schwartz

Baskin Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Cole Smead

Cole Smead

Smead Capital Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically